A detailed report from key House Committees blasts FDA’s role in advising, assessing, and providing accelerated approval in 2021 for Biogen’s controversial Alzheimer’s treatment Aduhelm (aducanumab). The critique calls for changes in agency interactions with manufacturers to more carefully document meetings and other communications and to clarify the agency’s role in advising sponsors on product testing and submissions.
